Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain and inflammatory conditions such as arthritis. However, both arthritis and many NSAIDs increase cardiovascular (CV) risks. The dose-dependency of the elevated CV risks of NSAIDs has not been well-studied. We tested the hypothesis that low but still effective doses of these drugs are void of CV side effects. As the model drug, we chose diclofenac because of its known high CV toxicity, as markers of CV risks, we assessed concentrations of cytochrome P450-mediated metabolites of arachidonic acid (ArA), and we used adjuvant arthritis as an experimental model of arthritis. Following 7 daily doses (2.5–15 mg/kg), the effective dosage range of diclofenac was identified (> 5 mg/kg/day). While 7 consecutive days of low therapeutic doses did not alter the CYP-mediated ArA metabolism, the highest dose of 15 mg/kg/day caused imbalances in ArA metabolic profiles toward cardiotoxicity by increasing the ratio of cardiotoxic 20-hydroxyeicosatetraenoic acid over cardioprotective epoxyeicosatrienoic acids. This is suggestive of dose-dependency of NSAID cardiotoxicity, and that low therapeutic doses may be void of CV side effects. Human studies are needed to examine the safety of low but effective doses of NSAIDs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aghazadeh-Habashi A, Asghar W, Jamali F (2015) Simultaneous determination of selected eicosanoids by reversed-phase HPLC method using fluorescence detection and application to rat and human plasma, and rat heart and kidney samples. J Pharm Biomed Anal 110:12–19
Aghazadeh-Habashi A, Asghar W, Jamali F (2017) Drug-disease interaction: effect of inflammation and nonsteroidal anti-inflammatory drugs on cytochrome P450 metabolites of arachidonic acid. J Pharm Sci. https://doi.org/10.1016/j.xphs.2017.09.020
Al-Lawati HR, Vakili M, Jamali F, Lavasanifar A (2016) Polymeric micelles for the delivery of diclofenac and its ethyl ester derivative. Pharm Nanotechnol 4(2):109–119
Al-Lawati H, Vakili MR, Lavasanifar A, Ahmed S, Jamali F (2019) Delivery and biodistribution of traceable polymeric micellar diclofenac in the rat. J Pharm Sci. https://doi.org/10.1016/j.xphs.2019.03.016
Arfe A et al (2016) Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 354:i4857. https://doi.org/10.1136/bmj.i4857
Asghar W, Aghazadeh-Habashi A, Jamali F (2017) Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis. Inflammopharmacology 1:1. https://doi.org/10.1007/s10787-017-0344-1
Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Venitz J (2000) Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 40(12):1399–1418
Dubé L, Caillon J, Gras-Le Guen C, Jacqueline C, Kergueris M, Granry J, Bugnon D (2003) Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model. Antimicrob Agents Chemother 47(11):3663–3666
e-CPS (2003) Compendium of pharmaceutical and specialties. The Canadian Drug Reference for Health Professionals Canadian Pharmacists Association, Ottawa
Gislason GH et al (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113:2906–2913. https://doi.org/10.1161/circulationaha.106.616219
Harirforoosh S, Jamali F (2005) Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat. Can J Physiol Pharmacol 83:85–90. https://doi.org/10.1139/y04-129
Harirforoosh S, Aghazadeh-Habashi A, Jamali F (2006) Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent. Clin Exp Pharmacol Physiol 33:917–924. https://doi.org/10.1111/j.1440-1681.2006.04464.x
Harirforoosh S, Asghar W, Jamali F (2014) Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 16:821–847
Jamali F, Brocks DR (1990) Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 19:197–217. https://doi.org/10.2165/00003088-199019030-00004
Jamali F, Kunz-Dober CM (1999) Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. Br J Clin Pharmacol 47:391–396
Jamali F, Alballa RS, Mehvar R, Lemko CH (1988) Longer plasma half-life for procainamide utilizing a very sensitive high performance liquid chromatography assay. Ther Drug Monit 10:91–96
Khazaeinia T, Jamali F (2003) A comparison of gastrointestinal permeability induced by diclofenac-phospholipid complex with diclofenac acid and its sodium salt. J Pharm Pharm Sci 6:352–359
Kulmatycki KM, Jamali F (2001) Therapeutic relevance of altered cytokine expression. Cytokine 14:1–10. https://doi.org/10.1006/cyto.2000.0827
Ling S, Lewanczuk RZ, Russell AS, Ihejirika B, Jamali F (2009) Influence of controlled rheumatoid arthritis on the action and disposition of verapamil: focus on infliximab. J Clin Pharmacol 49:301–311. https://doi.org/10.1177/0091270008328099
Node K et al (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276–1279
Piquette-Miller M, Jamali F (1995) Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. Drug Metab Dispos 23:240–245
Rainsford KD (1982) Adjuvant polyarthritis in rats: is this a satisfactory model for screening anti-arthritic drugs? Agents Actions 12:452–458
Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131–185. https://doi.org/10.1152/physrev.00021.2001
Sanaee F, Clements JD, Waugh AW, Fedorak RN, Lewanczuk R, Jamali F (2011) Drug-disease interaction: Crohn’s disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. Br J Clin Pharmacol 72:787–797. https://doi.org/10.1111/j.1365-2125.2011.04019.x
Stec DE, Mattson DL, Roman RJ (1997) Inhibition of renal outer medullary 20-HETE production produces hypertension in Lewis rats. Hypertension 29:315–319
Theken KN, Deng Y, Kannon MA, Miller TM, Poloyac SM, Lee CR (2011) Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metab Dispos 39:22–29. https://doi.org/10.1124/dmd.110.035287
van Staa TP, Rietbrock S, Setakis E, Leufkens HG (2008) Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J Intern Med 264:481–492. https://doi.org/10.1111/j.1365-2796.2008.01991.x
Wang JS et al (2006) Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res 98:962–969. https://doi.org/10.1161/01.res.0000217283.98806.a6
Woods A, Brull DJ, Humphries SE, Montgomery HE (2000) Genetics of inflammation and risk of coronary artery. Eur Heart J 21:1574–1583
Wu AH (2008) Cardiotoxic drugs: clinical monitoring and decision making. Heart 94:1503–1509. https://doi.org/10.1136/hrt.2007.133876
Yang L, Maki-Petaja K, Cheriyan J, McEniery C, Wilkinson IB (2015) The role of epoxyeicosatrienoic acids in the cardiovascular system. Br J Clin Pharmacol 80:28–44. https://doi.org/10.1111/bcp.12603
Yuan J, Ma H, Cen N, Zhou A, Tao H (2017) A pharmacokinetic study of diclofenac sodium in rats Biomed Rep 7:179–182. https://doi.org/10.3892/br.2017.942
Acknowledgements
This research was supported by a University of Alberta self-directed grant.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ahmed, S.A., Al-Lawati, H. & Jamali, F. Dose-dependency of the cardiovascular risks of non-steroidal anti-inflammatory drugs. Inflammopharmacol 27, 903–910 (2019). https://doi.org/10.1007/s10787-019-00621-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-019-00621-5